C R Bard Inc (BCR) : Stone Run Capital reduced its stake in C R Bard Inc by 1.44% during the most recent quarter end. The investment management company now holds a total of 27,300 shares of C R Bard Inc which is valued at $6 Million after selling 400 shares in C R Bard Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.C R Bard Inc makes up approximately 3.77% of Stone Run Capital’s portfolio.
Other Hedge Funds, Including , Sentry Investments Corp. reduced its stake in BCR by selling 13,400 shares or 16.5% in the most recent quarter. The Hedge Fund company now holds 67,800 shares of BCR which is valued at $14.8 Million. C R Bard Inc makes up approx 0.21% of Sentry Investments Corp.’s portfolio.Korea Investment Corp reduced its stake in BCR by selling 2,400 shares or 5.45% in the most recent quarter. The Hedge Fund company now holds 41,600 shares of BCR which is valued at $9.1 Million. C R Bard Inc makes up approx 0.07% of Korea Investment Corp’s portfolio.Jefferies Group boosted its stake in BCR in the latest quarter, The investment management firm added 1,867 additional shares and now holds a total of 4,930 shares of C R Bard Inc which is valued at $1.1 Million. C R Bard Inc makes up approx 0.04% of Jefferies Group’s portfolio. Massmutual Trust Co Fsbadv added BCR to its portfolio by purchasing 52 company shares during the most recent quarter which is valued at $11,370.Cadinha Co reduced its stake in BCR by selling 70,546 shares or 93.43% in the most recent quarter. The Hedge Fund company now holds 4,964 shares of BCR which is valued at $1.1 Million. C R Bard Inc makes up approx 0.27% of Cadinha Co’s portfolio.
C R Bard Inc closed down -1.11 points or -0.50% at $220.17 with 5,15,160 shares getting traded on Wednesday. Post opening the session at $222.23, the shares hit an intraday low of $219.705 and an intraday high of $222.79 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Barclays on May 24, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 224 from a previous price target of $212 .Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 212 from a previous price target of $195 .C R Bard Inc was Initiated by Nomura to “Neutral” on Mar 17, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.